News Search Results
Oct 29, 2025, 05:01 ET IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean market for the treatment of multiple myeloma. This partnership aims to provide a new therapeutic option for Korean patients with multiple myeloma, and GC Cell plans to sequentially pursue domestic regulatory approval and commercialization of Fucaso.
More news about: IASO Bio
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an
More news about: DelveInsight Business Research, LLP
Oct 27, 2025, 07:00 ET Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
GPRC5D. GPRC5D is highly expressed on multiple myeloma cells. However, in normal tissues, its expression is limited to plasma cells and hair follicle cells. Such a feature has made GPRC5D a promising safe and effective target for the treatment of multiple myeloma. The antigen recognition
More news about: IASO Bio
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically used. While targeted agents and autologous hematopoietic stem cell transplantation can slightly extend the overall survival of pPCL patients
More news about: CARsgen Therapeutics
Oct 17, 2025, 09:00 ET Precision Oncology Approaches Drive $312B Market Transformation
collaboration with Pfizer Inc. (NYSE: PFE) to evaluate the combination of cemsidomide and elranatamab for treating relapsed/refractory multiple myeloma. Under the agreement, Pfizer will supply elranatamab (ELREXFIO), a BCMAxCD3 targeted bispecific antibody, at no cost for C4 Therapeutics'
More news about: USA News Group
Oct 16, 2025, 08:00 ET TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.5 In multiple myeloma, these plasma cells proliferate and spread rapidly
More news about: Johnson & Johnson
Oct 15, 2025, 10:00 ET The Leukemia & Lymphoma Society, now Blood Cancer United, collaborates with The US Oncology Network to advance care in community cancer centers
founding in 1949, it has consistently evolved to better serve people affected by all 100-plus types of blood cancers — including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. Blood Cancer United offers free, trustworthy resources, personalized
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
stays[4]. Alternative drug delivery methods and targeted therapy approvals for lung cancer, breast cancer, and multiple myeloma demonstrate how precision oncology tools are accelerating patient access to breakthrough treatments[1]. These advances position
More news about: Equity Insider
Oct 15, 2025, 08:00 ET Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease and Idiopathic Inflammatory Myopathy
patients have been dosed with OM336 across investigator-initiated and company-sponsored clinical studies in oncology indications including multiple myeloma, and in immune-mediated indications including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP) and autoimmune bullous diseases. OM336
More news about: Ouro Medicines
Oct 14, 2025, 08:05 ET Clear Channel Outdoor and Blood Cancer United Team Up on Billboard Campaign to Reach More People Affected by Blood Cancer
founding in 1949, it has consistently evolved to better serve people affected by all 100-plus types of blood cancers—including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. Blood Cancer United offers free, trustworthy resources, personalized
More news about: Clear Channel Outdoor
Oct 09, 2025, 08:30 ET Canopy to be Highlighted at ASCO 2025 Quality Care Symposium
Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting
More news about: Canopy
Oct 08, 2025, 07:00 ET Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Oct 07, 2025, 20:15 ET CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
relapsed/refractory multiple myeloma (R/R MM) in an investigator-initiated trial (NCT05838131) have been published in The Lancet Haematology. The article was titled "GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre,
More news about: CARsgen Therapeutics
Oct 01, 2025, 17:31 ET CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight
Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers
More news about: DelveInsight Business Research, LLP
Oct 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Oct 01, 2025, 07:30 ET Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
inhibitor therapy for breast cancer. AUKELSO is approved for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable
More news about: Biocon Biologics